Antony Veena B, Nasreen Najmunnisa, Mohammed Kamal A, Sriram Peruvenba S, Frank Wolfgang, Schoenfeld Nicolas, Loddenkemper Robert
Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Florida, PO Box 100225, Gainesville, FL 32610-0225, USA.
Chest. 2004 Nov;126(5):1522-8. doi: 10.1378/chest.126.5.1522.
Patients with recurrent pleural effusions secondary to malignancy are subjected to pleurodesis if clinically indicated. Pleurodesis involves the introduction of a sclerosing agent into the pleural space. Talc is one of the most commonly used sclerosing agents in treating patients with recurrent, symptomatic malignant pleural effusions. However, the mechanisms whereby talc mediates pleural fibrosis remain unclear. We hypothesized that the intrapleural instillation of talc induces the pleural mesothelial production of basic fibroblast growth factor (bFGF), which is responsible for pleural fibrosis.
Samples of pleural fluid collected from 23 patients with malignant pleural effusions and 6 patients with congestive heart failure (control group) were included in this study. A tumor grading scale (1 to 9) was used to demonstrate the extent of the tumor. In vitro pleural mesothelial cells (PMCs) were activated with talc, and the conditioned medium was collected to evaluate bFGF levels by enzyme-linked immunosorbent assay. The bFGF-induced proliferation of fibroblasts was studied by [(3)H]thymidine incorporation. The messenger RNA expression of bFGF in talc-activated PMCs was determined by Northern analysis.
In this study, we demonstrated that patients who have undergone successful pleurodesis following intrapleural talc insufflation have significantly higher levels of bFGF in their pleural fluid compared to those who do not respond to pleurodesis. In addition, we found a significant negative correlation between bFGF levels and tumor size. Talc-activated PMCs produce significantly higher levels of bFGF compared to control, which correlates with bFGF messenger RNA expression in PMCs stimulated with talc. The neutralization of pleural fluids and conditioned medium from talc-stimulated PMCs with bFGF antibodies significantly inhibits the bFGF-induced proliferation of pleural fibroblasts.
An important outcome of this study was the finding that patients with extensive tumor involvement of the pleural mesothelium have a significantly lower pleural fluid bFGF response to talc compared to those who have limited involvement. Patients with limited pleural disease and higher bFGF responses go on to have successful pleurodesis, demonstrating that the presence of a mesothelium that is free of tumor enhances the possibility of success. In vitro PMCs stimulated with talc release biologically active bFGF.
对于因恶性肿瘤继发复发性胸腔积液的患者,若临床有指征则需进行胸膜固定术。胸膜固定术包括将硬化剂注入胸膜腔。滑石粉是治疗复发性、有症状的恶性胸腔积液患者最常用的硬化剂之一。然而,滑石粉介导胸膜纤维化的机制仍不清楚。我们推测胸膜腔内注入滑石粉可诱导胸膜间皮细胞产生碱性成纤维细胞生长因子(bFGF),而这一因子导致了胸膜纤维化。
本研究纳入了23例恶性胸腔积液患者和6例充血性心力衰竭患者(对照组)的胸水样本。采用肿瘤分级量表(1至9级)来显示肿瘤的范围。体外使用滑石粉激活胸膜间皮细胞(PMC),收集条件培养基,通过酶联免疫吸附测定法评估bFGF水平。通过[³H]胸腺嘧啶核苷掺入法研究bFGF诱导的成纤维细胞增殖。通过Northern分析确定滑石粉激活的PMC中bFGF的信使核糖核酸表达。
在本研究中,我们证明与未对胸膜固定术产生反应的患者相比,经胸膜腔内注入滑石粉后成功进行胸膜固定术的患者胸水中bFGF水平显著更高。此外,我们发现bFGF水平与肿瘤大小之间存在显著负相关。与对照组相比,滑石粉激活的PMC产生的bFGF水平显著更高,这与滑石粉刺激的PMC中bFGF信使核糖核酸表达相关。用bFGF抗体中和滑石粉刺激的PMC的胸水和条件培养基可显著抑制bFGF诱导的胸膜成纤维细胞增殖。
本研究的一个重要结果是发现,与胸膜间皮受累有限的患者相比,胸膜间皮有广泛肿瘤累及的患者对滑石粉的胸水bFGF反应显著更低。胸膜疾病有限且bFGF反应较高的患者随后成功进行了胸膜固定术,这表明不存在肿瘤的间皮的存在增加了成功的可能性。体外滑石粉刺激的PMC释放具有生物活性的bFGF。